<SEC-DOCUMENT>0001299933-17-000167.txt : 20170221
<SEC-HEADER>0001299933-17-000167.hdr.sgml : 20170221
<ACCEPTANCE-DATETIME>20170221134215
ACCESSION NUMBER:		0001299933-17-000167
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170220
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170221
DATE AS OF CHANGE:		20170221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NORDSON CORP
		CENTRAL INDEX KEY:			0000072331
		STANDARD INDUSTRIAL CLASSIFICATION:	GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC [3569]
		IRS NUMBER:				340590250
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-07977
		FILM NUMBER:		17624544

	BUSINESS ADDRESS:	
		STREET 1:		28601 CLEMENS RD
		CITY:			WESTLAKE
		STATE:			OH
		ZIP:			44145
		BUSINESS PHONE:		4408921580

	MAIL ADDRESS:	
		STREET 1:		28601 CLEMENS ROAD
		CITY:			WESTLAKE
		STATE:			OH
		ZIP:			44145
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_54606.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Nordson Corporation (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	February 20, 2017
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Nordson Corporation
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Ohio
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	0-7977
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	34-0590250
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	28601 Clemens Road, Westlake, Ohio
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	44145
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	440-892-1580
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 7.01 Regulation FD Disclosure.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On February 20, 2017, Nordson Corporation ("Nordson"), Viking Merger Corp. ("Merger Sub"), a wholly owned subsidiary of Nordson, Vention Medical Holdings, Inc. ("Vention") and VMHI Rep Services, LLC ("VMHI"), as stockholder representative, entered into an Agreement and Plan of Merger (the "Merger Agreement").  Pursuant to the terms of the Merger Agreement and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Vention will be merged with and into Merger Sub (the "Merger") effective as of the effective time of the Merger (the "Effective Time").  As a result of the Merger, Merger Sub will cease to exist and Vention will survive as a wholly owned subsidiary of Nordson.<br><br>Concurrently with the execution and delivery of the Merger Agreement, Vention has entered into an agreement with a third party whereby Vention will sell, prior to the Effective Time, all of the outstanding capital stock of Vention Medical, Inc. ("Vention Medical"), a wholly owned subsidiary of Vention, to such third party (the "DMS Transaction").<br><br>Under the terms of the Merger Agreement, Nordson will acquire Vention, excluding Vention Medical and certain subsidiaries of Vention Medical to sold pursuant to the DMS Transaction, on a cash-free and debt-free basis for an aggregate purchase price of $705 million, subject to certain adjustments (including a customary working capital adjustment).<br><br>The Merger Agreement contains customary representations, warranties and covenants made by Nordson, Merger Sub and Vention.  The respective Boards of Directors of Merger Sub and Vention have each unanimously determined that it is in the best interests of their respective stockholders to enter into the Merger Agreement, approved the execution, delivery and performance of the Merger Agreement and the consummation of the Merger and other transactions contemplated thereby, and, subject to the terms of the Merger Agreement, the Vention Board of Directors resolved to recommend approval of the Merger Agreement by its stockholders.<br>  <br>The consummation of the Merger is subject to customary closing conditions, including, among other things: (1) the approval of the Merger by holders of a majority of the outstanding shares of Vention; (2) the DMS Transaction shall have been consummated; (3) the absence of any law prohibiting, or any order, injunction or certain other legal impediments restraining, enjoining or otherwise prohibiting, the consummation of the Merger; (4) the receipt of the required regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (5) subject to certain materiality and other qualifications, the accuracy of the representations and warranties made by Vention and Nordson, respectively; (6) the performance in all material respects by Vention and Nordson, respectively, of its obligations under the Merger Agreement; and (7) in the case of Nordson&#x2019;s obligations to compete the Merger, the absence of any material adverse effect with respect to Vention since the date of the Merger Agreement.  The Merger Agreement may also be terminated by either Nordson or Vention if the closing does not occur by May 31, 2017. The merger is not conditioned upon Nordson&#x2019;s receipt of financing.  Nordson expects to fund the purchase price with cash on hand and new long-term debt.<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
d.) Exhibits<br><br>99.1 Press release of Nordson Corporation dated February 20, 2017.<br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Nordson Corporation
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	February 21, 2017
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Robert E. Veillette
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Robert E. Veillette
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Vice President, General Counsel & Secretary
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release of Nordson Corporation dated February 20, 2017.
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><img src="e43416-17521236549547b9ea_2.jpg">
</FONT>

<P align="left" style="font-size: 12pt"><B>Nordson Corporation Announces Agreement to Acquire Advanced Technologies Business of Vention
Medical</B>


<P align="left" style="font-size: 12pt; text-indent: 1%"><FONT style="font-size: 11pt">
</FONT>


<P align="left" style="margin-left:2%; font-size: 11pt"><I>Highly complementary business adds significant scale and enhances strategic capabilities of
existing Nordson MEDICAL platform</I>



<P align="left" style="margin-left:2%; font-size: 11pt"><I>Establishes Nordson as a leading supplier in rapidly growing minimally invasive interventional
delivery device and component market</I>



<P align="left" style="margin-left:2%; font-size: 11pt"><I>Strengthens existing and expands Nordson relationships with multiple blue chip medical
technology OEM customers</I>



<P align="left" style="margin-left:2%; font-size: 11pt"><I>Enhances Nordson top and bottom line growth rates and is accretive to GAAP earnings per share in
fiscal year 2017</I>


<P align="left" style="font-size: 11pt"><B>Westlake, Ohio, USA &#150; February&nbsp;20, 2017 &#151; </B><U>Nordson Corporation</U> (Nasdaq: NDSN) announced
today that it has entered into a definitive agreement to acquire <U>Vention Medical</U>&#146;s Advanced
Technologies (Vention AT) business, a leading designer, developer and manufacturer of minimally
invasive interventional delivery devices, catheters and advanced components for the global medical
technology market, for $705&nbsp;million in an all cash transaction. Headquartered in Salem, New
Hampshire, Vention AT reported sales of $150&nbsp;million and EBITDA of $48&nbsp;million for the trailing
twelve months ended January&nbsp;31, 2017. The transaction will be financed through cash and debt.


<P align="left" style="font-size: 11pt">&#147;We are extremely pleased to add a high quality, differentiated market leader in minimally invasive
delivery devices and components to Nordson&#146;s existing medical platform,&#148; said Michael F. Hilton,
Nordson President and Chief Executive Officer. &#147;This acquisition aligns with the medical growth
strategy we have consistently articulated, brings significant scale to what is already one of
Nordson&#146;s fastest growing businesses, and enhances strategically important capabilities including
design and development, extrusion, complex medical tubing and balloon manufacturing, nitinol
forming and other specialty material expertise. We see Vention AT as an ideal complement to our
current offering of single-use fluid management components, biomaterial delivery devices, and high
end cannula and tubing, and we are excited to bring our combined capabilities to the many leading
medical OEM customers we share.&#148; Vention AT employs approximately 775 people and will operate as
part of Nordson&#146;s Advanced Technology Systems segment.


<P align="left" style="font-size: 11pt"><U><B>Benefits of the Transaction</B></U>



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Adds scale in attractive and rapidly growing end markets: </B>Offers leadership position in
minimally invasive interventional delivery end markets that are growing at a high single digit
rate.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Enhances strategic manufacturing and product capabilities: </B>Adds design, development, prototyping
and regulatory expertise; high end tubing, catheter and balloon manufacturing expertise;
material expertise.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Expands product portfolio: </B>Offers more than 20,000 SKUs to more than 1,500 customers with a
significant portion of single use consumables that generate a steady stream of recurring
revenue. Highly complementary to Nordson&#146;s current offering of single-use fluid management
components, biomaterial delivery devices, and high end cannula and tubing.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Expands applications and end markets served: </B>Brings expertise in coronary/peripheral vascular,
minimally invasive, structural heart, electrophysiology, urology, kyphoplasty and several other
high growth therapeutic areas.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Delivers attractive financial benefits: </B>Expected to accelerate Nordson top and bottom line
growth and be accretive to EBITDA margins. Nordson expects $0.05 to $0.10 accretion to EPS in
fiscal year 2017, including estimated purchase accounting charges.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Provides customer synergies: </B>Deepens and expands Nordson&#146;s exposure to large OEM&#146;s and emerging
innovators. Selected cross-selling opportunities.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Provides presence in key medical regions: </B>Footprint in Minneapolis, Ireland and Israel, among
others.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Aligns with articulated acquisition strategy: </B>Follows other successful Nordson acquisitions in
the medical space including Value Plastics, Micromedics, LinkTech Quick Couplings and Avalon
Catheters.



<P align="left" style="margin-left:2%; font-size: 11pt"><B>Further balances Nordson&#146;s Advanced Technology Systems segment around less cyclical end markets.</B>


<P align="left" style="font-size: 11pt"><U><B>Transaction Details and Advisors</B></U>
<BR>
Vention Medical is a portfolio company of KRG Capital Partners. Vention Medical consists of the
Advanced Technologies (Vention AT) business and a separate Device Manufacturing Services (Vention
DMS) business, a contract manufacturing operation not core to Nordson&#146;s strategic direction.
Nordson&#146;s acquisition of Vention AT is expected to close during Nordson&#146;s second fiscal quarter,
pending customary regulatory clearances.


<P align="left" style="font-size: 11pt">As is customary in transactions of this nature, certain information regarding Vention AT is subject
to restrictions on disclosure until closing. Following the close of the transaction, additional
financial information, including audited financial statements, will be provided by Nordson in its
filings with the Securities and Exchange Commission.


<P align="left" style="font-size: 11pt">Morgan Stanley & Co. LLC is serving as financial advisor to Nordson, and Jones Day is serving as a
legal advisor.


<P align="left" style="font-size: 11pt"><U><B>Conference Call and Webcast for Investors</B></U>
<BR>
Nordson management will provide additional background on the Vention AT transaction and other
recent fiscal year 2017 acquisitions at 8:30 am eastern on Tuesday, February&nbsp;21 as part of the
company&#146;s previously scheduled first quarter results conference call and webcast. The conference
call may be accessed by dialing US/Canada Toll-Free (877)&nbsp;303-1593 or (973)&nbsp;935-8149. Participants
will need to specify Conference ID # 64914948. A webcast of the call may be accessed via Nordson&#146;s
website at <U>www.nordson.com/investors</U>.


<P align="left" style="font-size: 11pt">A slide deck with additional information on Vention AT and other recent fiscal 2017 acquisitions is
also available at <U>www.nordson.com/investors</U>.


<P align="left" style="font-size: 11pt"><U><B>About Nordson</B></U>
<BR>
Nordson Corporation engineers, manufactures and markets differentiated products and systems used to
dispense, apply and control adhesives, coatings, polymers, sealants, biomaterials, and other
fluids, to test and inspect for quality, and to treat and cure surfaces. These products are
supported by application expertise and direct global sales and service. Nordson serves a wide
variety of consumer non-durable, durable and technology end markets including packaging, nonwovens,
electronics, medical, appliances, energy, transportation, construction, and general product
assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has
operations and support offices in nearly 40 countries. Visit Nordson on the web at
www.nordson.com, www.twitter.com/Nordson&#151;Corp or <U>www.facebook.com/nordson</U>.


<P align="left" style="margin-right:2%; font-size: 11pt">Forward Looking Statements
</FONT><BR>
<FONT style="font-size: 9pt"><I>This press release may contain &#147;forward-looking statements&#148; within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by
word such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;predicts,&#148; &#147;projects,&#148; or &#147;potential&#148; or the negative of these words and phrases or
similar words or phrases which are predictions of or indicate future events or trends and which do
not relate solely to historical matters. Forward-looking statements relate to expectations,
beliefs, projections, future plans and strategies of, and anticipated events or trends and similar
expressions related to, newly acquired businesses to be integrated and contribute to future growth
and profit expectations. While forward-looking statements reflect our good faith beliefs,
assumptions and expectations, they are not guarantees of future performance, and are subject in the
future to unforeseen uncertainties and risks that could cause actual results to differ materially
from those contained in any forward-looking statement.</I>
</FONT>

<P align="left" style="font-size: 9pt"><I>Such risks and uncertainties include the occurrence of any event, change or other circumstances
that could delay the closing of the proposed transaction; the possibility of non-consummation of
the proposed transaction and termination of the merger agreement; the failure to obtain Vention
Medical shareholder approval of the proposed transaction or to satisfy any of the other conditions
in the merger agreement; the possibility that a governmental entity may prohibit, delay or refuse
to grant a necessary regulatory approval in connection with the proposed transaction; the risk that
stockholder litigation in connection with the proposed transaction may affect the timing or
occurrence of the proposed transaction or result in significant costs of defense, indemnification
and liability; adverse effect on our common stock because of the failure to complete the proposed
transaction; Vention ATs or our respective businesses experiencing disruptions due to
transaction-related uncertainty or other factors making it more difficult to maintain relationships
with employees, business partners or governmental entities; the risk that Vention Medical incurs
liabilities related to the sale of the DMS business; significant transaction costs related to the
proposed transaction; our ability to integrate our acquisitions and realize expected synergies; and
other important risks and uncertainties described under &#147;Risk Factors&#148; in Item&nbsp;1A of our annual
report on Form&nbsp;10K and any updates to those factors set forth in our subsequent quarterly reports
on </I><I>Form 10-Q</I><I> or current reports on </I><I>Form 8-K</I><I>. We make these statements as of the date of this
disclosure, and undertake no obligation to update them unless otherwise required by law.</I>


<P align="center" style="font-size: 9pt"><FONT style="font-size: 11pt"># # #</FONT>




<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e43416-17521236549547b9ea_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e43416-17521236549547b9ea_2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "H S # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJX?(L\Q:3PN2YMBD[6>'R[%UEK:W\.C+NMCP\7Q1PU@')8[B'(\&X_$L5FV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*6!R++</4]U63E5IX:-24M-92FY-ZMMZF+:^&_#MB@CLM!T6S11@):Z78VZ
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MFV-CE>.P]/)\QR#!8O%8_EC6K+^T<)2K8.I@I8JG/#QCB)TDHR4I*''+Z7>
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M*GB*</:TX\U.4*]3G:@M%%%?F9^P!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?._[6-W=V'[._Q0N["ZN+*[@T6S:&ZM9Y;:XA8ZYI2%HI
MX&2:-BK,I,;*Q4D9P37B_P"R;\4O$^E7%M\!_BO=2OXHMO#6F>+?AQK][<23
M'QEX'UBRBU.WM(KFYP]SJ.@PRR0[$DF<VEI?V81!X<N;BZ]@_:[_ .3;_BK_
M -@.R_\ 3[I-<!\0/@_J7Q&^"'PG\4>";@Z5\6?AOX0\)>)?A[K$#6\<\UY;
MZ!I=Q<^';A[M39R6>M"WBCC2_'V)+Z*T^UNNG2ZC%<:)KEY7UD_>?2RC:WWZ
MKMV)Z_):?/5V[V/>_CE--;_!3XO75M--;7-O\+_'UQ;W$$CP3P31>%-5DBFB
ME0K)%+$ZJZ.C*Z.H8$$5%\!IYKGX)?".YNIYKFYN/AKX(N+FXN)'FGGFE\.:
M<TDTTLA9Y99'RTCNS.[DLQ);)\33XQ6/QF_93^+>O_9VTKQ-I?PQ^(NA>-O#
M<L<MO=>'_$^G^$-6CU"V>UN";F.TN6'VO3S,SRBVD%M<,+^UO88O-?B3XWO?
M"/[&?P1TRQUG_A&?^%AZ%\)OA[?^*,R@^&M%UGPPE[KNK'RE>0HND:3>6<GD
MA;A8;R66W=)HXW16=DMGSV_#^FAW5K]#ZQU#]H#X(:5JTFB:C\5_ 5IJ<,TM
MM<V\OB;2@MG<P.\<]O?7 N3:V-Q!)&Z3P7<T,L+J5E1&XKO-6\7^$] TF'7]
M=\3^']%T*Y:U2WUK5M9T[3M)G:]7?9K#J-Y<0V<K7:_-;!)F,X(,6[(KX_\
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M[[NZ[=5?;S^^_P#5[GUSXN^,GPI\!WG]F^,?B%X3\/:GLCD.EZAK5G'JB13
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MYE^SQ_V3&)6^]SSGD#KG.:/*7/4\#&/QSU_GZ]ZK >/SR_@_!\.TN#<)_:V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
